All conditions

Glaucoma

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1655
Trials on record
150
Recruiting now
1
Australian sites
12
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Glaucoma →

Get alerts when Glaucoma trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Glaucoma

Glaucoma is a condition that damages the optic nerve, which is the nerve that carries visual information from your eye to your brain. This damage is most often caused by pressure building up inside the eye, though it can sometimes occur even when eye pressure appears normal. The tricky thing about glaucoma is that it usually develops very slowly and without any pain or obvious symptoms in the early stages. Side vision tends to be affected first, which means many people don't notice changes until the condition has already progressed. If left undetected or untreated, glaucoma can lead to permanent vision loss.

Glaucoma is one of the leading causes of vision loss in Australia, affecting around 300,000 Australians. Because it often runs in families, people with a close relative who has glaucoma are at higher risk. It becomes more common with age, particularly in people over 50, though it can occur at any age. Many Australians are living with glaucoma without knowing it, which is why regular eye check-ups with an optometrist or ophthalmologist are so important for early detection.

There is currently no cure for glaucoma, but in most cases it can be managed effectively. The goal of treatment is to lower eye pressure and slow or stop further damage to the optic nerve. Common approaches include daily eye drops to reduce eye pressure, laser treatments, and in some cases surgery. The right approach will depend on the individual, and a specialist eye doctor called an ophthalmologist will work with you to find a suitable plan. With consistent monitoring and treatment, many people with glaucoma are able to maintain useful vision for a long time.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Glaucoma in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Glaucoma currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Glaucoma.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Glaucoma by country. Australia is highlighted.

Showing the top 10 of 45 countries with trial sites.

Clinical trials for Glaucoma

Showing 152 of 152 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01157364 · Allergan Phase 2 · 10 countries Completed
Completed Phase 2 Est. completion 27 July 2016
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇩🇪 DE🇮🇱 IL🇵🇭 PH🇸🇬 SG +2 more

Who might be able to join this trial: - You have been diagnosed with open angle glaucoma or high pressure in your eyes (ocular hypertension) Who may not be able to join: - You have other health conditions that are not well managed or under control - You plan to wear contact lenses at any point during the study Import...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01177098 · Allergan Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 1 February 2012
🇦🇺 AU🇨🇿 CZ🇩🇪 DE🇭🇺 HU🇮🇱 IL🇷🇺 RU🇪🇸 ES🇬🇧 GB +1 more

**Who might be able to join this trial:** - You have been diagnosed with high eye pressure or glaucoma in both eyes - You need treatment to lower the pressure in both of your eyes **Who may not be able to join:** - You have an active or returning eye disease (other than glaucoma/high eye pressure) that could affect th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06833060 · Lumibird Medical (Quantel Medical, Ellex Medical, Optotek) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇦🇺 AU

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with open-angle glaucoma (a type of glaucoma where the drainage angle in the eye is open) or high eye pressure, and your doctor considers you a suitable candidate for a standard laser eye treatment called SLT - You have m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00221897 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇺🇸 US

Who might be able to join this trial: - People who are healthy (with or without short-sightedness/myopia), or people who have been diagnosed with glaucoma, are suspected of having glaucoma, or have high eye pressure (with or without short-sightedness/myopia) - People who are 18 years of age or older (there is no upper...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02014389 · Sheba Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇱 IL

**Who might be able to join this trial:** - You are between 18 and 80 years old. - You are willing and able to sign a consent form agreeing to take part. - Your pupils react normally to light (they get smaller when light shines on them). **Who may not be able to join:** - Your corneas (the clear front part of your eye...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02157025 · Nova Southeastern University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - Children between the ages of 5 and 8 years old - Children who have previously been seen at Nova Southeastern University's The Eye Care Institute and have been diagnosed with suspected glaucoma or an abnormality of the optic nerve - Children who are able and willing to attend 2 st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02290795 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2025
🇧🇪 BE

Who might be able to join this trial: - People who are willing to sign an informed consent form agreeing to take part in the trial - People who are 18 years of age or older - People who have glaucoma, are scheduled for a trabeculectomy (a type of eye surgery for glaucoma), are scheduled to receive an ocriplasmin inject...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02959242 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇩🇪 DE

"Who might be able to join this trial: - People diagnosed with glaucoma (a condition that damages the optic nerve), high eye pressure (ocular hypertension), or who are considered a glaucoma suspect (showing some signs that may indicate a risk of glaucoma) Who may not be able to join: - People who are under 18 years of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03423758 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2026
🇦🇹 AT

**Who might be able to join this trial:** - People aged 50 or older who have been diagnosed with pseudoexfoliation syndrome (a condition where flaky material builds up in the eye) or a related type of glaucoma - People aged 21 or older who have been diagnosed with a specific type of glaucoma caused by a narrow or clos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03648814 · Prince of Songkla University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇹🇭 TH

**Who might be able to join this trial:** - You have been diagnosed with a type of glaucoma caused by abnormal blood vessel growth (called neovascular glaucoma) - Your eye pressure is higher than 21 mmHg and your doctor has recommended a specific type of eye surgery called a trabeculectomy - You are at least 18 years o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03675412 · Wills Eye Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 90 years old - People who have been diagnosed with primary open angle glaucoma (mild, moderate, or advanced stage) - People who have healthy eyes with no eye disease **Who may not be able to join:** - People who have eye or general health condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03870230 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇦🇹 AT

Who might be able to join this trial: - People diagnosed with primary open-angle glaucoma, confirmed by abnormal appearance of the optic nerve and abnormal visual field test results, with eye pressure of 21 mmHg or higher recorded on at least three occasions before treatment - People diagnosed with normal tension glau...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03933631 · Montefiore Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have high eye pressure or open-angle glaucoma and are scheduled to have cataract surgery combined with a specific procedure called KDB (a type of drainage channel procedure) at Montefiore Medical Center, performed by one specific surgeon. Who may not be able to join:...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04024293 · Sensimed AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇭 CH

**Who might be able to join this trial:** - People who are willing and able to give informed consent to take part - People who have been clinically diagnosed with primary open angle glaucoma (a common type of glaucoma where the eye's drainage angle is open), including a type called normal tension glaucoma - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04232982 · Centre hospitalier de l'Université de Montréal (CHUM) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2034
🇨🇦 CA

Who might be able to join this trial: - Adults aged 18 to 80 years old - People who are able to understand and sign a consent form agreeing to take part - People who are able to attend follow-up visits throughout the study - People whose doctor has recommended them for a specific type of eye implant called a Boston ker...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04354545 · University of California, Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are currently using one or more eye drops to lower pressure in their eyes for glaucoma - People who describe experiencing discomfort on the surface of their eyes - People whose doctor has prescribed Xiidra as part of their regular care Who may not be able to join: - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04396002 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇺🇸 US

Who might be able to join this trial: - People who are already enrolled in one of two specific research studies: the "Early Detection of Glaucoma Progression using a Novel Individualized Approach" study, or the "African Descent and Glaucoma Evaluation (ADAGES) IV" study (as a patient participant) - People with no diagn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04416724 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇨🇦 CA

**Who might be able to join this trial:** - People who have pseudoexfoliation syndrome — a condition where a flaky, dandruff-like material builds up in the eye — confirmed by an eye doctor using a specialised lamp examination - People whose eye doctor has decided that their eye pressure needs to be lowered, either bec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04519619 · Bayer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇯🇵 JP

**Who might be able to join this trial:** - People who have been diagnosed with neovascular glaucoma (a type of eye condition where abnormal blood vessels block fluid drainage, raising pressure in the eye) - People who have already received treatment with a medicine called aflibercept, given by injection into the eye,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04553523 · Alcon Research Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have a cataract that can be treated with surgery, where even with glasses or contact lenses their vision is still 20/40 or worse (meaning they would struggle to read a standard eye chart clearly) - People who have been diagnosed with a common type of glaucoma calle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04635020 · Helsinki University Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2023
🇫🇮 FI

**Who might be able to join this trial:** - People who have given their signed consent to participate - People who have a clinically significant cataract (a cataract that is affecting vision or eye health) - People who are able to attend follow-up visits over a 12-month period - People who have mild to moderate exfoli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04846140 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been diagnosed with primary open angle glaucoma or normal tension glaucoma affecting both eyes - People whose glaucoma has caused a measurable loss in their side or peripheral vision in at least one eye, as confirmed b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04957329 · Rigshospitalet, Denmark Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - You are over 18 years old - You speak Danish - You have been diagnosed with open angle glaucoma or high eye pressure (ocular hypertension) - Your average eye pressure reading is 22 mmHg or higher **Who may not be able to join:** - You have a history of significant eye diseas...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04967989 · University of Pittsburgh Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 June 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are in good health - People whose eyes (one or both) have been diagnosed with high-risk high eye pressure (pressure above 21 mmHg) without signs of glaucoma damage to the optic nerve - People whose eyes (one or both) have been diagnosed with mild...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05039684 · Instituto Universitario de Oftalmobiología Aplicada (Institute of Appl... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇸 ES

**Who might be able to join this trial:** - People diagnosed with primary open-angle glaucoma or high eye pressure (ocular hypertension), as defined by the Early Manifest Glaucoma Trial criteria - People aged 18 or older - People who have signed a consent form agreeing to take part - People who have been using one of t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05136950 · Zhongshan Ophthalmic Center, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2023
🇨🇳 CN

**Who might be able to join this trial:** - Children between 18 months and 14 years of age - Children who were diagnosed with a cataract present from birth (a clouding of the lens in the eye that a child is born with) - Children who had surgery to remove that cataract when they were between 2 and 24 months old **Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05180994 · Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇦 CA

Who might be able to join this trial: - You are between 18 and 80 years old - You are scheduled for your first-ever corneal transplant surgery (surgery to replace the clear front part of the eye) - You are able to understand and agree to the terms of the study - You are able to apply eye drops yourself, or you have a c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05206877 · Stanford University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You are able to understand and sign a consent form agreeing to take part in the study - You have been diagnosed with a condition affecting the optic nerve, specifically glaucoma, NAION (a condition where blood flow to the optic nerve is blocked), or optic disc drusen (calcium dep...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05264818 · Fondation Ophtalmologique Adolphe de Rothschild Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who give their consent to take part in the study - For the glaucoma group: People who have primary open angle glaucoma in both eyes, meaning they have vision field damage caused by damage to the optic nerve - For the comparison group: People who have no optic nerve pro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05275738 · Umeå University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇸🇪 SE

**Who might be able to join this trial:** *General criteria across both parts of the trial:* - Adults aged 18 or older who have been diagnosed with a specific type of glaucoma (called primary open-angle glaucoma or pseudoexfoliation glaucoma) - People whose vision is at a certain minimum level (good enough to read a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05340647 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇳🇴 NO

**Who might be able to join this trial:** - You must be 18 years of age or older (there is no upper age limit) - You are already scheduled to have a specific type of eye surgery to help with glaucoma (such as a Preserflo microshunt, trabeculectomy, or a similar minimally invasive procedure) - You are able to cooperate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05344274 · University of Maryland, Baltimore Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 years or older - People whose eye examination shows an open drainage angle (a specific measurement of eye structure graded 3 or 4 on the Shaffer classification scale) - People whose glasses or contact lens prescription falls between +3.00 and -8.00 diopters -...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05370287 · Food and Drug Administration (FDA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇺🇸 US

Who might be able to join this trial: - You are 21 years of age or older. - You are able to follow simple instructions during an eye imaging scan (similar to a standard eye exam). - You are able to understand and sign a consent form agreeing to take part. - You have been diagnosed with primary open-angle glaucoma, also...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05401357 · Amneal Pharmaceuticals, LLC Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2022
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give their consent freely and follow the study's requirements. - Adults aged 18 or older, of any gender. - People with a body mass index (BMI) of 18.50 or higher (a measure of body weight relative to height). - People who have been diagnose...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05405868 · University College, London Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with early to moderate open-angle glaucoma (including normal tension glaucoma or pseudoexfoliation glaucoma) in at least one eye within the last 12 months - People whose eye examination shows an open drainage angle in the eye (a specific struct...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05426044 · Christopher Kai Shun Leung Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
Hong Kong

Who might be able to join this trial: - People who are 18 years of age or older - People whose best vision with glasses or contact lenses is at least 20/40 - People whose eye pressure measured at 24 mmHg or below at both the screening and baseline appointments - People who have shown progressive thinning of certain lay...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05439161 · Prof. Dr. Herbert Reitsamer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇦🇹 AT

Who might be able to join this trial: - You have been diagnosed with a type of open-angle glaucoma (such as primary open-angle glaucoma, pseudoexfoliation glaucoma, or pigmentary dispersion glaucoma) - Your eye surgeon has determined that you are medically suitable for both types of surgery being studied (trabeculectom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05500469 · Oogziekenhuis Rotterdam Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇳🇱 NL

Who might be able to join this trial: - You must be over 18 years old - You must be willing to give your consent to participate in the study - You must have an artificial lens implanted in your eye (meaning you have previously had cataract surgery) - You must have been diagnosed with one of the following types of glauc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05523622 · State University of New York at Buffalo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign and date a consent form agreeing to take part in the study - You are willing to follow all study procedures and be available for the full length of the study - You are a man or woman between 18 and 99 years old - You are in good enough general...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05564091 · Nova Eye, Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇩🇪 DE🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with mild to moderate primary open-angle glaucoma (the most common type of glaucoma, where fluid doesn't drain properly from the eye) - Your eye test results match what is expected for mild to moderate glaucoma - You are currently using between 1 and 4...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05624398 · Vold Vision P.L.L.C Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 45 years of age or older - You have a cataract in both eyes that is affecting your vision - You have been diagnosed with mild open-angle glaucoma, with eye pressure of 25 mmHg or below while taking 1 to 3 glaucoma medications - Your glaucoma has been considered stable...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05685485 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 December 2024
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - Your glaucoma or high eye pressure is not well controlled with current treatment - Your doctor has planned for you to have an Ahmed valve implant (a small drainage device placed in the eye) - You have been diagnosed with a specific type of gla...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05694858 · Universiti Kebangsaan Malaysia Medical Centre Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 11 December 2026
🇲🇾 MY

**Who might be able to join this trial:** - People aged 18 years or older - People who need a blood draw (needle into a vein) as part of preparation for an eye procedure **Who may not be able to join:** - People who have previously had a sensitivity reaction or allergic reaction to lignocaine (a type of local anaesthe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05696561 · New World Medical, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇱 CL Costa Rica Honduras

Who might be able to join this trial: - People who have been recommended for cataract surgery. - People who have been diagnosed with open-angle glaucoma in at least one eye, with an eye pressure reading between 22 and 34 mmHg when not taking any eye pressure-lowering medications. Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05710198 · Omikron Italia S.r.l. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2026
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older who have signed a consent form agreeing to take part in the trial. - People diagnosed with open-angle glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma. - People whose vision in the study eye, when corrected with glasses or contact lenses,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05726058 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have vision in both eyes - People who are able to give their informed consent to participate - People who are either healthy volunteers, have been referred for a glaucoma assessment, or have been diagnosed with moderate to severe glaucoma in at least o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05786196 · Nova Eye, Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇪 DE🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People aged 22 or older at the time of their surgery - People who have been diagnosed with mild to moderate primary open-angle glaucoma (a common type of glaucoma) - People whose condition makes them a suitable candidate for a specific type of eye surgery called canaloplasty...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05801471 · Centervue SpA Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 November 2028
🇮🇹 IT

**Who might be able to join this trial:** - People who have glaucoma-related damage to the optic nerve (the nerve connecting the eye to the brain) in both eyes - People aged between 40 and 90 years old - People whose vision, even with glasses or contact lenses, meets a certain minimum level of clarity (confirm with tri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05844384 · 59th Medical Wing Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 March 2024
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and have been diagnosed with open-angle glaucoma or high eye pressure (called ocular hypertension) - You are currently using no more than 2 eye drop medications to lower the pressure in your eyes - Your eye condition has been stable over the p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05874258 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
Hong Kong

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been diagnosed with primary open angle glaucoma or normal tension glaucoma affecting both eyes - People whose glaucoma has caused a specific type of partial vision loss (called a relative scotoma) in at least one eye,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05885022 · Myra Vision Inc. Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇮🇳 IN🇲🇽 MX Panama

**Who might be able to join this trial:** - You have been diagnosed with open angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma - Your eye pressure (measured before the procedure) is between 18 and 45 mmHg - Your vision test shows a certain level of sight loss, specifically a visual field mean deviatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05924477 · University of Pennsylvania Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have glaucoma that is not well controlled with medication and who are scheduled to have a glaucoma drainage device (a small implant to help drain fluid from the eye) placed, either alone or combined with cataract surgery - People whose eye anatomy is suitable for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05954403 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2037
🇫🇷 FR

Who might be able to join this trial: - Newborns and children from birth to 7 years old who have one of these eye conditions: anophthalmia (missing one or both eyes), microphthalmia (abnormally small eyes), aniridia (missing or underdeveloped iris), or anterior segment dysgenesis (a problem with the front part of the e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06000865 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
Hong Kong

**Who might be able to join this trial:** - You have been diagnosed by an eye doctor with moderate to severe glaucoma affecting both eyes (either open-angle glaucoma, including normal tension glaucoma, or angle-closure glaucoma), confirmed by specific vision field and eye scan tests - Your vision and any vision loss ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06016712 · Faculty Hospital Kralovske Vinohrady Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇿 CZ

**Who might be able to join this trial:** - People who are pregnant with a healthy, normal pregnancy (no complications) - People who are pregnant for the first time and have not previously given birth **Who may not be able to join:** - People who have previously given birth one or more times - People whose pregnancy h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06057051 · Glaukos Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a type of glaucoma called primary open-angle glaucoma - You have your natural lens in your eye, or you have had your natural lens replaced with an artificial one (for example, after cataract surgery) - You are 35 years old or older Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06066645 · Glaukos Corporation Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with open-angle glaucoma or ocular hypertension (high eye pressure). - People whose eye pressure in the study eye falls within the required range set by the trial (confirm with trial site for specific numbers). Who may not be able to join: - People...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06077253 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇩🇰 DK

Who might be able to join this trial: - People diagnosed as a "primary angle closure suspect," meaning a specific eye examination (gonioscopy, done in a dark room) shows that the drainage angle in the eye is partially blocked over at least half of its circumference, eye pressure is below 21 mmHg (within the normal rang...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06124521 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who identify as Black or African American - People who have already completed the screening examination part of this study Who may not be able to join: - People who are currently experiencing severe eye pain rated higher than 8 out of 10 - People who have had a sudden los...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06128720 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who are able to follow the study schedule and complete all required visits and tasks - People who have clinical signs of optic neuropathy (damage to the nerve that carries vision signals from the eye to the brain) - People who are able to read...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06139523 · Duke University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** **Group 1 – Healthy adults:** - Adults aged 18 or older who are willing and able to agree to take part in the study - People who are generally healthy with no known eye problems other than needing glasses or contact lenses - Women of childbearing age who complete a standard pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06201455 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 40 and 85 years, of any gender - People who have been diagnosed with primary open-angle glaucoma (a specific type of glaucoma) - People whose eye pressure is controlled at 24 mmHg or below, using between 1 and 4 eye drop medications to manage it - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06223048 · Amydis Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2024
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of glaucoma called primary open angle glaucoma in both eyes - You are able to focus your gaze steadily (fixate) during an eye exam - A doctor has confirmed that both of your eyes show signs of glaucoma-related damage to the optic n...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06227611 · Fondazione G.B. Bietti, IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 May 2022
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with glaucoma that has caused damage to the nerve at the back of your eye (optic nerve) and thinning of a specific layer of cells in your eye (ganglion cell layer) **Who may not be able to join:** - You are under 18 years of age - You are unable to re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06243497 · Zhongshan Ophthalmic Center, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been definitively diagnosed with glaucoma, with no restrictions on age or gender - People whose eye pressure is 21 mmHg or higher, even while taking the maximum amount of glaucoma medication that can be safely tolerated - People whose eye pressure is below 21...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06246136 · Elios Vision, Inc. Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇧🇪 BE🇫🇷 FR🇩🇪 DE🇳🇱 NL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You can be male or female. - You are 40 years old or older. - You have been diagnosed with mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma, or pigmentary glaucoma. - You have a cataract that affects your vision and is suitable for a common type of cat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06267274 · Amneal Pharmaceuticals, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2025
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to give their consent freely and follow the study's requirements - Adults aged 18 years or older (male or female) - People who have been diagnosed with chronic open-angle glaucoma or high eye pressure (ocular hypertension) in both eyes - People who...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06274593 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older of any gender - People who have glaucoma and are currently being followed and treated in the ophthalmology department at Nantes University Hospital in France - People whose visual field test results show a mean defect (a measure of vision loss across t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06289491 · Massachusetts Eye and Ear Infirmary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have a cataract that is affecting your vision and you are already planning to have cataract surgery. - You have been diagnosed with mild to moderate open-angle glaucoma, including types called pigmentary glaucoma or pseudoexfoliation glaucoma. - Your glaucoma is classifi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313749 · Sanoculis Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People aged 40 to 85 years old (male or female) - People who have been diagnosed with a type of glaucoma called primary open-angle glaucoma, where eye pressure is not well controlled even while taking multiple eye pressure-lowering medications, with eye pressure readings betw...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06353542 · Hospital Clinic of Barcelona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are between 40 and 80 years old - You have a family history of glaucoma (a relative has been diagnosed with glaucoma) - You are willing to take part in the study - You are willing to sign a consent form agreeing to participate **Who may not be able to join:** - You are n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06492538 · Zhongshan Ophthalmic Center, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have glaucoma and are scheduled for certain types of eye angle surgery, either on its own or combined with other eye procedures such as laser treatment, lens removal, or lens implantation - People who are able to have a series of pre-surgery eye examinations using spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06523751 · Wuerzburg University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇪 DE

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with one of these types of glaucoma: primary open angle glaucoma, pigmentary glaucoma, or pseudoexfoliation glaucoma - Your eye pressure is not well controlled even when taking the maximum amount of glaucoma medicatio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06549010 · Envision Health Technologies, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2024
🇺🇸 US

**Who might be able to join this trial:** - You are between 25 and 70 years old - If joining as a "normal" (non-glaucoma) participant: you have no current or past eye conditions that could affect your vision or visual field, such as retina problems, glaucoma, cataracts, or keratoconus - If joining as a "normal" partici...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06577857 · Sanoculis Ltd Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
Armenia

Who might be able to join this trial: - You have previously had a specific eye procedure called the MIMS® inferonasal surgery, and that surgery took place no more than 24 months before joining the trial. Who may not be able to join: - There are no specific exclusion criteria listed for this trial (confirm with trial s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06682962 · Okuvision GmbH Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇩🇪 DE

**Who might be able to join this trial:** - You are willing to take part and can sign a consent form before the study begins - You are 40 years old or older - You have been diagnosed with one of these types of glaucoma in the eye being studied: primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06685211 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older. - People who are able to attend all required study visits and follow the study schedule. - People who have been diagnosed with primary open-angle glaucoma (including normal tension or low tension types), with vision test results falling within a speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06691555 · Davinci LTD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇬🇪 GE

Who might be able to join this trial: - People who have previously had a specific eye surgery involving a silicone tube shunt placed in the suprachoroidal space (a layer inside the eye) - People who are willing and able to take part in a one-time observational follow-up study - People who are able to understand and agr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06712758 · Visionair Oogzorg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇧🇪 BE

Who might be able to join this trial: - People who have been diagnosed with both glaucoma and an age-related cataract Who may not be able to join: - People who are not willing to sign a consent form agreeing to take part in the trial - People who only have one functional (working) eye - People who have a condition aff...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06760169 · Hôpital Privé de la Baie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older who agree to take part and have signed a consent form - People who have a cataract that significantly affects their vision and have been recommended for cataract surgery - People who have been diagnosed with primary open-angle glaucoma, or a related t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06792422 · Glostrup University Hospital, Copenhagen Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2028
🇩🇰 DK

Who might be able to join this trial: - People who can read and speak Danish - People who are 45 years old or older at the time of joining the trial - People whose vision in the study eye is at a level considered functional (a visual acuity score of 0.5 or above) - People who have been diagnosed with a specific type of...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06808633 · Clínica Rementería Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 September 2026
🇪🇸 ES

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with open-angle glaucoma (a type of glaucoma where the drainage angle of the eye remains open, but eye pressure is too high and there is damage to the optic nerve), where the treating doctor has recommen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06822738 · AbbVie Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with glaucoma in the eye being studied, AND it is not controlled even when using the maximum number of eye pressure-lowering medications (four or more types, or fewer if some medications cannot be used due to side effects or other reasons), AND at lea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06844292 · Medical University of Graz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 March 2027
🇦🇹 AT

**Who might be able to join this trial:** - People who have glaucoma where surgery is needed to reduce eye pressure, and who also have a cloudy lens (cataract) where cataract surgery is recommended - People who are medically suitable to have both eye surgeries performed - People who are not expected to need any additio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06848946 · Glaukos Corporation Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: - You have a cataract in one eye that is significant enough to need cataract surgery (a procedure called phacoemulsification). - You have been diagnosed with either open-angle glaucoma (including certain types such as those related to protein buildup or pigment in the eye) or high...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06854198 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - Black people who are 50 years of age or older - Hispanic people who are 65 years of age or older - People who have diabetes and are 50 years of age or older - People who have visited the Federally Qualified Health Center (a type of community health clinic) within the past month...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865235 · Faculdade de Ciências Médicas de Minas Gerais Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇧🇷 BR

**Who might be able to join this trial:** - You are 40 years old or older - You are already a patient in the glaucoma department at one of the hospitals taking part in this study - You need cataract surgery, confirmed by an eye exam showing your vision is 20/40 or worse - You have been diagnosed with Primary Open Angle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06882356 · Massachusetts Eye and Ear Infirmary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2030
🇺🇸 US

**Who might be able to join this trial:** - You have diabetes and are already having your eyes screened for diabetic retinopathy (eye damage caused by diabetes) using a specific AI-based system called LumineticsCore (by Digital Diagnostics) as part of your regular care at a primary care clinic. - You are able and willi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06883123 · Prairie Eye Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with mild to moderate open-angle glaucoma (a common type of glaucoma where fluid drains too slowly from the eye) - People who are currently using a specific combination of two eye drop medications — Cosopt and Latanoprost — as...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06885827 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2027
🇸🇪 SE

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of joining - People who have been diagnosed by an eye doctor with one of these specific types of glaucoma: Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Pseudoexfoliation Glaucoma — in one or both eyes - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06921317 · IVIEW Therapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** **All participants must meet these general criteria:** - People who are willing to take part and have signed a written consent form - People aged 18 to 75 years old (inclusive), of any gender - People who have been diagnosed with primary open-angle glaucoma (a common type of g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06934577 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2030
🇺🇸 US

**Who might be able to join this trial:** - People who speak English, Spanish, Arabic, Chinese, French, Hindi, Finnish, Albanian, Russian, or Tagalog **Who may not be able to join:** - People who are experiencing significant eye pain - People who have had a sudden decrease in their vision within the past week - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06952153 · University of Medicine and Pharmacy at Ho Chi Minh City Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇻🇳 VN

**Who might be able to join this trial:** - People aged 40 years or older - People who have a specific type of eye angle blockage (where the drainage angle of the eye is closed for more than half its circumference) - People diagnosed with glaucoma that has caused damage to the optic nerve along with loss of vision in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06953349 · Barnet Dulaney Perkins Eye Centers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇺🇸 US

Who might be able to join this trial: - People who have glaucoma and have previously had one of the following eye procedures: CEIOL, OMNI, or Hydrus implant — with the device chosen because they were using more than one glaucoma eye drop before surgery - People who have at least 3 years of follow-up records from that p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06963684 · Twin Cities Eye Consultants Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 40 years or older, of any gender - People who have been diagnosed in both eyes with either high eye pressure (ocular hypertension), suspected glaucoma, or mild open-angle glaucoma, as defined by the American Academy of Ophthalmology guidelines - People who are not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06976034 · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 November 2029
🇫🇷 FR

**Who might be able to join this trial:** **For people with an eye condition:** - Adults between 18 and 80 years old, male or female - People who have an eye condition affecting the cornea, the surface of the eye, the lens (such as cataracts), or glaucoma — or who have had or are planning refractive surgery (such as l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06979752 · Hôpital Privé de la Baie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 February 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who have a cataract and early-to-moderate pseudoexfoliation glaucoma (a specific type of glaucoma caused by a condition where flaky material builds up in the eye) and are already scheduled for cataract surgery on its own. - People whose visual field test (a specific e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06991270 · Sight Sciences, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
Panama

**Who might be able to join this trial:** - You are 45 years of age or older - You have a cataract that affects your vision and need cataract surgery, OR you have already had cataract surgery at least 6 months ago - The pressure in your eye is within a specific range — either at least 21 mmHg without eye pressure-lowe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06991712 · Christopher Kai Shun Leung Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
Hong Kong

**Who might be able to join this trial:** - You have been diagnosed with glaucoma - You are 18 years of age or older - Your vision (with glasses or contacts if needed) is 20/40 or better - Your eye pressure is below 21 mmHg (within the normal range) - Your visual field (side vision) test results show only mild to moder...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06993597 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with primary open-angle glaucoma (a common type of glaucoma where fluid drainage in the eye is reduced), or people with no history of glaucoma (who would participate as a comparison group) - People whose eye exami...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07009236 · iSTAR Medical Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
Honduras🇬🇧 GB

**Who might be able to join this trial:** - People aged 20 or older, of any sex - People who have been diagnosed with open angle glaucoma in the eye being studied - People whose eye's drainage angle (the angle between the iris and cornea) is classified as "open" or "wide open" according to a standard grading scale use...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07036510 · EyeD Pharma Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
Panama

Who might be able to join this trial: - People who are able to give their consent to participate after being fully informed about the trial. - People who are in good general and mental health, without any ongoing significant medical concerns in their medical history. - People who have been diagnosed with open-angle gla...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07063537 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇦 CA

**Who might be able to join this trial:** - You must be older than 18 years of age - You must have been diagnosed with a specific type of glaucoma called primary open-angle glaucoma - You must be able to complete a standard eye test that checks your field of vision - You must be able to understand and agree to take par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07075718 · Glaukos Corporation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with open-angle glaucoma or high eye pressure (ocular hypertension) in the eye being studied Who may not be able to join: - People who have previously had a type of glaucoma surgery involving a cut or incision in the eye being studied - People who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07119580 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇹🇼 TW

**Who might be able to join this trial:** - Adults aged 18 years or older - People with no diagnosis of glaucoma or high eye pressure (for the healthy control group) - People who have been diagnosed with a form of glaucoma or high eye pressure and have been using glaucoma eye drops or medication for less than 3 months...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07145073 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with glaucoma, with vision test results (Humphrey Visual Field 24-2) showing a mean deviation between -22 dB and -5 dB and a Visual Field Index between 10% and 90%, with reliable test results at screeni...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07147647 · Select Eye Care Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You are an adult of Black African descent who is scheduled to have a treatment called DSLT on one or both eyes. - You have been diagnosed with mild to moderate primary open-angle glaucoma (a common type of glaucoma where the drainage in the eye becomes less effective over tim...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07149740 · Optos, PLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇺🇸 US

Who might be able to join this trial: This trial has four different groups. You may qualify for one of them: **Retinal Disease Group** - You are 22 years of age or older - You are able to read and understand the consent form and are willing to sign it - Your vision in the study eye is at least 20/400 (even with glass...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07152132 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who are older than 40 years of age - People who have a specific type of glaucoma called primary open-angle glaucoma (POAG) and have previously had an uncomplicated cataract operation where an artificial lens was placed in the eye - People whose glaucoma is not adequate...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07206628 · Laboratoires Thea Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇮🇹 IT

Who might be able to join this trial: - You must be an adult aged 18 or older, male or female - You must have been diagnosed with open-angle glaucoma in both eyes - You must have been prescribed glaucoma eye drops that come in an EASYGRIP® bottle for at least 6 weeks, using only that one medication - You must be willin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07209410 · Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 65 years old who have been diagnosed with open-angle glaucoma or high eye pressure (ocular hypertension) - People who are currently using the eye drop medication netarsudil 0.02%/latanoprost 0.005% as their only glaucoma treatment, for at least 2 to 6 w...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07217678 · University of Miami Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have open-angle glaucoma, or are suspected of having open-angle glaucoma, in the eye being studied - People who have had their natural lens replaced with an artificial lens (such as after cataract surgery) in the eye being studied, and who meet a specific eye heal...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07218796 · SpyGlass Pharma, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with mild to moderate open-angle glaucoma or high eye pressure (ocular hypertension) - You are planning to have cataract removal surgery - If you are a woman who could become pregnant, you must have a negative pregnancy test at the start of the trial a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07220876 · Avisi Technologies Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇿🇦 ZA🇺🇸 US

Who might be able to join this trial: - People diagnosed with open angle glaucoma, pseudoexfoliative glaucoma (a type caused by a build-up of protein deposits), or pigmentary glaucoma (a type caused by pigment particles blocking drainage) - People whose eye pressure, measured at a pre-surgery appointment, falls between...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07235592 · Santen SAS Not Applicable · 8 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇦🇹 AT🇧🇪 BE🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇹 PT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 to 85 years old (male or female) - People diagnosed with primary open-angle glaucoma where eye pressure is not well controlled even while taking the maximum amount of glaucoma medications that can be tolerated, and whose eye pressure measures between 18 mmHg an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07243665 · Singapore Eye Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇸🇬 SG

**Who might be able to join this trial:** - You are 21 years old or older and have been diagnosed with diabetes (either type 1 or type 2) - A camera can be used to take photos of the back of your eyes at the clinic, even if the photos do not come out perfectly clear - You are willing and able to sign a consent form agr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07281391 · Mann Eye Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are an adult who has been diagnosed with pigmentary dispersion syndrome (a condition where pigment cells shed into the eye) with higher-than-normal eye pressure, or mild to moderate pigmentary glaucoma with signs of damage to the optic nerve and vision. - Your eye pressu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07290244 · Life Biosciences Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have clear eye structures and whose pupils can be safely dilated for an eye examination. - People who are able to understand the study and sign a consent form. - People who are between 40 and 85 years old. - People who are willing and able to follow the study schedule,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07303257 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older who have been recommended for glaucoma surgery - People whose planned surgery is one of three specific procedures: Preserflo™ MicroShunt with mitomycin C, trabeculectomy with mitomycin C, or non-penetrating deep sclerectomy with mitomycin C - People wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07310719 · Lagos State Health Service Commission Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
Nigeria

**Who might be able to join this trial:** - You are 18 years of age or older. - You have recently been diagnosed with a type of glaucoma called Primary Open Angle Glaucoma (POAG) or a condition called Ocular Hypertension (OHT), where the pressure in your eye is higher than normal. - The pressure in your eye has been me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07322965 · Institut Catala de Retina Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇪🇸 ES

**Who might be able to join this trial:** - You have been diagnosed with chronic glaucoma (any type) in at least one eye, with confirmed damage to the structure of the eye shown by imaging tests. - Your glaucoma has also caused measurable loss in your field of vision, detected through a standard visual field test. - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07325240 · Mayo Clinic Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with elevated eye pressure (OHT) or mild-to-moderate open-angle glaucoma in both eyes, based on eye tests done within the past year (having one condition in each eye is also acceptable) - Your eye pressure is between 18 and 34 mmHg in both eyes, eithe...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07325552 · Medical University of Bialystok Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇵🇱 PL

**Who might be able to join this trial:** - Only one eye per participant will be included in the study - You have a cataract that your doctor considers significant enough to need treatment - You have glaucoma or higher-than-normal eye pressure that is currently being managed with one to four eye pressure-lowering medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07335211 · Huons Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇰🇷 KR

Who might be able to join this trial: - Adults aged 19 years or older - People who have been diagnosed with primary open-angle glaucoma (a common type of glaucoma where fluid pressure builds up gradually) or ocular hypertension (higher-than-normal pressure in the eye) - People who have been fully informed about the stu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07354009 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older (any gender) - You have been diagnosed with open-angle glaucoma in the eye being studied - You have been diagnosed with cataracts in the eye being studied and are considered a suitable candidate for cataract removal surgery, with vision in that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07354477 · Qlaris Bio, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with mild to moderate open-angle glaucoma, mild to moderate normal-tension glaucoma, or stable non-proliferative diabetic retinopathy in at least one eye. - People whose vision, even with glasses or contact lenses, meets a minimum level of 20/20...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07355491 · Intalight, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇺🇸 US

I'll present the eligibility criteria for each of the four groups in this trial separately, as each group has different requirements. --- **GROUP 1: Normal (Healthy) Eyes Group** Who might be able to join this trial: - People who are 22 years of age or older at the time of signing the consent form - People who are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359547 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇧🇪 BE🇩🇪 DE🇵🇹 PT

**Who might be able to join this trial:** - People who are over 40 years of age - People who have been diagnosed with one of these specific types of glaucoma: primary open angle glaucoma, normal tension glaucoma, pigment dispersion glaucoma, or pseudoexfoliative glaucoma - People whose glaucoma is not adequately contr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07364929 · National University of Singapore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇸🇬 SG

**Who might be able to join this trial:** **For people with glaucoma:** - People who have been diagnosed with a specific type of glaucoma called primary open-angle glaucoma, where a recent vision field test showed results better than -12 dB in at least one eye - People whose central (straight-ahead) vision is still in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07396441 · Universiti Sains Malaysia Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 May 2026
🇲🇾 MY

Who might be able to join this trial: - People who were diagnosed with Juvenile Open-Angle Glaucoma (a type of eye condition affecting younger people) between the ages of 15 and 40 years old at the time of diagnosis - People who have been following their prescribed glaucoma treatment and have reached their target eye p...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07400926 · Glaukos Corporation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with open-angle glaucoma - People who are 18 years of age or older Who may not be able to join: - People who are currently pregnant or breastfeeding Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07409077 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are between 18 and 95 years old - You have been diagnosed with glaucoma and your eye pressure is currently well controlled - You have blind spots or areas of reduced vision very close to the centre of your vision (within a very small area around where you focus) - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07425496 · The New York Eye & Ear Infirmary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - You are having cataract surgery, glaucoma surgery, or both, at a Mount Sinai Health System hospital or clinic. Who may not be able to join: - You are under 18 years old. - You are currently pregnant. - You are not able to make your own medical decisions independently. - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07428668 · Ophthalmology Associates, Fort Worth Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender. - People who are able and willing to attend follow-up eye appointments for 6 months after the procedure. - People who are willing to sign a consent form approved by the relevant ethics review board. - People who have been diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07447011 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 July 2026
🇪🇬 EG

**Who might be able to join this trial:** - You have been diagnosed with obstructive sleep apnea (a condition where breathing repeatedly stops and starts during sleep) - You are considered obese (have a higher than healthy body weight) - You have been diagnosed with a type of glaucoma called open-angle glaucoma with hi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07454447 · Minia University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with primary open-angle glaucoma (a common type of glaucoma where the drainage angle in the eye is open but not working properly), including a form that can occur in younger people - People who have already had a specific type of eye surgery tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07455786 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇪🇬 EG

Who might be able to join this trial: - People who have had combined cataract removal surgery (phaco) together with a procedure called GATT (a type of glaucoma surgery). - People who have had cataract removal surgery (phaco) combined with a procedure called goniopuncture (another type of eye procedure). Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07462000 · Military Institute od Medicine National Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 January 2027
🇵🇱 PL

Who might be able to join this trial: - You must be 18 years of age or older. - You must be scheduled to have cataract surgery (a procedure to remove the cloudy lens in your eye and replace it with an artificial one). - You must be able to read and sign a consent form agreeing to take part. - If joining the glaucoma gr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07495852 · Glaukos Corporation Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with either high eye pressure (ocular hypertension) or a type of glaucoma called open-angle glaucoma in the eye being studied Who may not be able to join: - People who have previously had a surgical cut-based glaucoma operation in the eye being stu...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07496957 · Medical University of Bialystok Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇵🇱 PL

**Who might be able to join this trial:** - You are over 21 years old - You have been diagnosed with one of these specific types of glaucoma: Primary open angle glaucoma, Normal tension glaucoma, Pigment dispersion glaucoma, or Pseudoexfoliative glaucoma - Your glaucoma is not well controlled even with the maximum amou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07510087 · Marc Toeteberg-Harms Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with glaucoma, including open-angle, closed-angle, primary, or secondary types - People who are 18 years of age or older, with no maximum age limit - Both men and women are eligible to participate Who may not be able to join: - People who do not ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07523139 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 30 and 80 years old (inclusive) - You have been diagnosed with a type of eye condition called primary angle-closure disease (a condition related to the drainage angle in the eye), OR you have healthy eyes with normal drainage angles and are joining as a compar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07539675 · Zhongnan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of glaucoma called primary angle-closure glaucoma (PACG) - You are 50 years old or older (any gender can participate) - *(For Case Group A)* You are already scheduled for glaucoma surgery, and during that surgery the supporting fi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07580014 · Zhongshan Ophthalmic Center, Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 April 2027
🇨🇳 CN

Who might be able to join this trial: - People in the **control group**: Healthy individuals with no history of eye surgery, normal eye pressure (below 21 mmHg), and no significant cupping or asymmetry of the optic nerve in either eye - People in the **observation group**: Individuals who have been diagnosed by a glauc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07588152 · Indiana University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with either ocular hypertension (higher-than-normal eye pressure) or open-angle glaucoma (a common type of glaucoma) - People who have had an eye examination within the past year - For those with glaucoma: test result...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07592923 · Kazakh Eye Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 August 2026
🇰🇿 KZ

Who might be able to join this trial: - You have been diagnosed with glaucoma - You are 18 years old or older - Your glaucoma is not well controlled even with eye drops or other medications - Your doctor has decided that a specific type of laser treatment (called MP-CPC Laser) is the right treatment for you Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07592988 · Kazakh Eye Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 August 2026
🇰🇿 KZ

**Who might be able to join this trial:** - People who have been diagnosed with glaucoma - People aged 18 years or older - People whose glaucoma is not adequately controlled with current eye medications - People for whom a doctor has decided that a specific laser treatment (called MP-CPC Laser) is the appropriate cours...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07661329 · YS Life Science Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a type of glaucoma called primary open-angle glaucoma, or with high eye pressure (ocular hypertension), in both eyes - Both of your eyes need treatment, and you are able to stop or switch your current eye pressur...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07662759 · Kukje Pharma Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are 19 years of age or older - You have been diagnosed with a type of glaucoma called primary open-angle glaucoma, or with higher-than-normal eye pressure (ocular hypertension) - You are currently using, or have previously used, a combination of three eye pressure-loweri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07674069 · Buckinghamshire Healthcare NHS Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇬🇧 GB

Who might be able to join this trial: - You attend a glaucoma outpatient clinic - You need a visual field test (a test that checks your range of vision), and your doctor has planned for you to have the standard version of this test (called "SITA-STANDARD") - You are 18 years old or older, of any gender - You are able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07700498 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent to participate. - People aged between 40 and 85 years old. - People of any gender (male or female). - People who have never received any treatment for glaucoma — including no eye drops, laser procedures, or surgery to l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07722910 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender, whether or not they have type 2 diabetes or related eye problems, who are able to keep their head still during a specialised eye scan called iris OCTA - People who are willing to take part and have signed a written consent form - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Glaucoma. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Glaucoma Australia is the national body dedicated to glaucoma awareness and patient support.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.